Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations

Recruiting

Phase 2

PARP InhibitionStudy of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations

Sponsor:

Rana McKay, MD

Code:

NCT05498272

Conditions

Prostate Cancer

BRCA1 Mutation

BRCA2 Mutation

Prostatic Adenocarcinoma

High-Risk Cancer

Eligibility Criteria

Sex: Male

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Olaparib

LHRH agonist

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-08. This information was provided to ClinicalTrials.gov by Rana McKay, MD on 2025-07-28.